Abstract
The depletion in circulating dendritic cells (DCs) and inverse correlation with viral load have been described in human immunodeficiency virus (HIV)-infected patients. The aim of this study was to investigate whether the DC blood count in antiretroviral-treated patients might be predictive of viral load control independent of CD4+ T cell count. Plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were enumerated using a newly developed flow cytometric assay based on TruCOUNT. A significant reduction of circulating pDCs and mDCs was detected both in untreated and -treated subjects. The probability of experiencing viral load increase according to pDC, and CD4 count at baseline was evaluated in 39 treated patients. Individuals with lower baseline pDCs were more likely to have an increase of HIV-RNA during the 30 month follow-up in comparison with patients with high pDCs (p < 0.001). In particular, the pDC measurement may be useful in the context of a high CD4 count, to distinguish the patients who have virological failure despite high CD4 counts. These findings suggest that in treated patients the enumeration of circulating DCs, especially pDC count, can augment the predictive value of CD4 measurement in predicting virologic failure.
Keywords: HIV, dendritic cells, antiretroviral therapy, innate immunity, CD4, pDC
Current HIV Research
Title: Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count
Volume: 6 Issue: 1
Author(s): Claudio M. Mastroianni, Miriam Lichtner, Raffaella Rossi, Maria C. Rizza, Fabio Mengoni, Ilaria Sauzullo, Anna P. Massetti, Giuseppe Luzi, Anne Hosmalin and Vincenzo Vullo
Affiliation:
Keywords: HIV, dendritic cells, antiretroviral therapy, innate immunity, CD4, pDC
Abstract: The depletion in circulating dendritic cells (DCs) and inverse correlation with viral load have been described in human immunodeficiency virus (HIV)-infected patients. The aim of this study was to investigate whether the DC blood count in antiretroviral-treated patients might be predictive of viral load control independent of CD4+ T cell count. Plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were enumerated using a newly developed flow cytometric assay based on TruCOUNT. A significant reduction of circulating pDCs and mDCs was detected both in untreated and -treated subjects. The probability of experiencing viral load increase according to pDC, and CD4 count at baseline was evaluated in 39 treated patients. Individuals with lower baseline pDCs were more likely to have an increase of HIV-RNA during the 30 month follow-up in comparison with patients with high pDCs (p < 0.001). In particular, the pDC measurement may be useful in the context of a high CD4 count, to distinguish the patients who have virological failure despite high CD4 counts. These findings suggest that in treated patients the enumeration of circulating DCs, especially pDC count, can augment the predictive value of CD4 measurement in predicting virologic failure.
Export Options
About this article
Cite this article as:
Mastroianni M. Claudio, Lichtner Miriam, Rossi Raffaella, Rizza C. Maria, Mengoni Fabio, Sauzullo Ilaria, Massetti P. Anna, Luzi Giuseppe, Hosmalin Anne and Vullo Vincenzo, Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count, Current HIV Research 2008; 6 (1) . https://dx.doi.org/10.2174/157016208783571937
DOI https://dx.doi.org/10.2174/157016208783571937 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Action of Hypertonic Saline Resuscitation in Severe Sepsis and Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Infection and Anemia
Infectious Disorders - Drug Targets Editorial (Thematic Issue: Immunotherapy in Central Nervous System)
Current Pharmaceutical Biotechnology Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery A Clinical Update and Global Economic Burden of Rheumatoid Arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Tetherin Antagonism by Primate Lentiviral Nef Proteins
Current HIV Research Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery Combinatorial Protein Biochemistry for Therapeutics and Proteomics
Current Pharmaceutical Biotechnology Inspired Nitric Oxide and Modulation of Oxidative Stress During Cardiac Surgery
Current Drug Safety Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Complications of Diabetes: An Insight into Genetic Polymorphism and Role of Insulin
Recent Patents on Inflammation & Allergy Drug Discovery Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Protein & Peptide Letters Role of in vivo and in vitro Tests in the Diagnosis of Severe Cutaneous Adverse Reactions (SCAR) to Drug
Current Pharmaceutical Design Quantitative Structure-Activity Relationship (QSAR) Analysis to Predict Drug-Drug Interactions of ABC Transporter ABCG2
Mini-Reviews in Medicinal Chemistry Peripheral Immunosenescence and Central Neuroinflammation: A Dangerous Liaison - A Dietary Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets N-acetylcysteine Versus Placebo for Treating Nail Biting, a Double Blind Randomized Placebo Controlled Clinical Trial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gene Therapy: How to Target the Kidney. Promises and Pitfalls
Current Gene Therapy The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Flavonoids as Prospective Aromatase Inhibitors in Breast Cancer Prevention/ Therapy
Current Molecular Pharmacology